Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ROSIGLITAZONE vs ROZANOLIXIZUMAB-NOLI: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ROSIGLITAZONE vs ROZANOLIXIZUMAB-NOLI: Safety Overview

Metric ROSIGLITAZONE ROZANOLIXIZUMAB-NOLI
Total FAERS Reports 45,976 349
Deaths Reported 4,661 4
Death Rate 10.1% 1.1%
Hospitalizations 23,675 84
Average Patient Age 60.2 yrs 55.1 yrs
% Female Patients 42.8% 63.3%
FDA Approval Date Jan 25, 2013 N/A
Marketing Status Discontinued Prescription